Want to see HK:1477 full AI Analyst Report?
1477 Stock Chart & Stats
HK$7.55
-HK$0.01(-0.25%)
At close: 4:00 PM EST
HK$7.55
-HK$0.01(-0.25%)
Day’s Range― - ―
52-Week RangeHK$4.04 - HK$12.23
Previous CloseN/A
Volume1.11M
Average Volume (3M)3.41M
Market Cap
HK$3.97B
Enterprise ValueHK$5.69K
Total Cash (Recent Filing)HK$547.50M
Total Debt (Recent Filing)HK$187.62M
Price to Earnings (P/E)―
Beta1.31
Next Earnings
Aug 20, 2026EPS Estimate
-0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.20
Shares Outstanding836,331,900
10 Day Avg. Volume1,456,522
30 Day Avg. Volume3,406,832
Financial Highlights & Ratios
PEG Ratio0.68
Price to Book (P/B)1.43
Price to Sales (P/S)6.54
P/FCF Ratio-14.66
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.07
Revenue Forecast (FY)HK$1.10B
Bulls Say, Bears Say
Bulls Say
Revenue Growth TrajectoryA ~44% YoY revenue acceleration in 2025 signals durable commercial traction in core ophthalmology markets. Sustained top-line growth supports scale, allows fixed R&D and SG&A to be absorbed, and materially improves the company's pathway toward operating leverage and eventual cash-flow break-even if execution continues.
Gross Margin SustainabilityA ~44% gross margin indicates structural pricing power or favorable product mix in its ophthalmology portfolio. Persistent mid/high gross margins provide a durable cushion to cover operating expenses as revenue grows, improving the odds that incremental sales will translate into improved operating income over the medium term.
Conservative Balance SheetA debt-to-equity near 0.05 reflects conservative leverage and meaningfully lower fixed financing obligations. This financial flexibility supports continued investment in R&D and commercialization, reduces refinancing risk during negative earnings periods, and increases resilience versus peers with higher leverage.
Bears Say
Negative Cash GenerationConsistent negative operating cash flow and roughly -359M FCF in 2025 show the business cannot self-fund growth today. Persistent cash burn forces reliance on external financing, limits internal reinvestment capacity, and creates execution risk if capital markets tighten or funding terms deteriorate.
Sustained UnprofitabilityA roughly -20% net margin and negative EBIT/EBITDA indicate the company has not reached profitable operations despite revenue gains. Continued losses depress returns on equity and require either sustained margin improvement or persistent external support before shareholders see durable earnings or cash returns.
Dependence On External CapitalReliance on external funding creates dilution and timing risk: future financing availability, cost, or covenant terms could constrain strategy. This dependency reduces strategic optionality, increases execution risk for clinical and commercial programs, and can force trade-offs if market conditions worsen.
Ocumension Therapeutics News
1477 FAQ
What was Ocumension Therapeutics’s price range in the past 12 months?
Ocumension Therapeutics lowest stock price was HK$4.04 and its highest was HK$12.23 in the past 12 months.
What is Ocumension Therapeutics’s market cap?
Ocumension Therapeutics’s market cap is HK$3.97B.
When is Ocumension Therapeutics’s upcoming earnings report date?
Ocumension Therapeutics’s upcoming earnings report date is Aug 20, 2026 which is in 35 days.
How were Ocumension Therapeutics’s earnings last quarter?
Ocumension Therapeutics released its earnings results on Mar 26, 2026. The company reported -HK$0.046 earnings per share for the quarter, beating the consensus estimate of -HK$0.081 by HK$0.035.
Is Ocumension Therapeutics overvalued?
According to Wall Street analysts Ocumension Therapeutics’s price is currently Overvalued.
Does Ocumension Therapeutics pay dividends?
Ocumension Therapeutics does not currently pay dividends.
What is Ocumension Therapeutics’s EPS estimate?
Ocumension Therapeutics’s EPS estimate is -0.03.
How many shares outstanding does Ocumension Therapeutics have?
Ocumension Therapeutics has 836,331,900 shares outstanding.
What happened to Ocumension Therapeutics’s price movement after its last earnings report?
Ocumension Therapeutics reported an EPS of -HK$0.046 in its last earnings report, beating expectations of -HK$0.081. Following the earnings report the stock price went down -0.996%.
Which hedge fund is a major shareholder of Ocumension Therapeutics?
Currently, no hedge funds are holding shares in HK:1477
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ocumension Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
29.56%
12-Months-Change
Fundamentals
Return on Equity
-4.33%
Trailing 12-Months
Asset Growth
7.75%
Trailing 12-Months
Company Description
Ocumension Therapeutics
Based in the People's Republic of China, Ocumension Therapeutics functions as a dedicated ophthalmic pharmaceutical platform. This company, along with its subsidiaries, is committed to the research, progression, and market introduction of therapeutic solutions for individuals with various eye conditions. Its extensive product offerings target treatments for disorders such as blepharitis, infectious and allergic conjunctivitis, dry eye syndrome, cataracts, glaucoma, ocular hypertension, post-surgical inflammation, uveitis, retinitis pigmentosa, age-related macular degeneration, corneal graft rejection, myopia, and optic neuritis. By December 31, 2021, Ocumension Therapeutics boasted a pipeline of 20 drug assets. The company, founded in 2017, maintains its headquarters in Suzhou, China.
Technical Analysis
Jiangsu Recbio Technology Co., Ltd. Class H
―
Mabpharm Limited
―
Zhaoke Ophthalmology Ltd.
―
Transcenta Holding Limited
―
Shandong Boan Biotechnology Company., Limited. Class H
―